Delving into the Latest Updates on Human umbilical cord-derived mesenchymal stem cell therapy(Children'S Hospital Of Chongqing Medical University) with Synapse

Overview

Basic Info

Drug Type

Stem cell therapy

Synonyms-

Target-

Mechanism-

Therapeutic Areas

Congenital DisordersRespiratory DiseasesOther Diseases

Active Indication

Bronchopulmonary Dysplasia

Inactive Indication-

Originator Organization

Children’S Hospital Of Chongqing Medical University

Active Organization

Children’S Hospital Of Chongqing Medical University

Inactive Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

This is a follow-up study to investigate the long-term safety and efficacy of human umbilical cord -derived mesenchymal stem cells (hUC-MSCs), for the treatment of BPD in premature infants. Subjects who participated in and completed the initial stage of the PhaseⅠtrial (NCT03558334 ) will be followed-up until 48 months after the hUC-MSCs transplantation.

Start Date01 Jul 2018

Sponsor / Collaborator

Children’S Hospital Of Chongqing Medical University

100 Clinical Results associated with Human umbilical cord-derived mesenchymal stem cell therapy(Children'S Hospital Of Chongqing Medical University)

Login to view more data

100 Translational Medicine associated with Human umbilical cord-derived mesenchymal stem cell therapy(Children'S Hospital Of Chongqing Medical University)

Login to view more data

100 Patents (Medical) associated with Human umbilical cord-derived mesenchymal stem cell therapy(Children'S Hospital Of Chongqing Medical University)

Login to view more data

100 Deals associated with Human umbilical cord-derived mesenchymal stem cell therapy(Children'S Hospital Of Chongqing Medical University)

Login to view more data